Tuesday, February 11, 2020 11:31:58 AM
Posted by ABMN Staff on Feb 11th, 2020 // No Comments
Bausch Health Companies logoBausch Health Companies (NYSE:BHC) had its target price dropped by investment analysts at Morgan Stanley from $34.00 to $32.00 in a research report issued to clients and investors on Tuesday, BenzingaRatingsTable reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s target price would suggest a potential upside of 14.78% from the stock’s current price.
A number of other research firms have also recently issued reports on BHC. Barclays restated a “buy” rating and issued a $33.00 price objective on shares of Bausch Health Companies in a research report on Sunday, January 26th. Piper Jaffray Companies boosted their price target on shares of Bausch Health Companies from $30.00 to $39.00 and gave the company an “overweight” rating in a research report on Monday, December 30th. Zacks Investment Research cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating and set a $33.00 price target on the stock. in a research report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Bausch Health Companies in a research report on Monday, December 23rd. Finally, TheStreet upgraded shares of Bausch Health Companies from a “d+” rating to a “c” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $34.06.
BHC stock opened at $27.88 on Tuesday. The firm’s 50-day moving average price is $28.97 and its two-hundred day moving average price is $25.42. Bausch Health Companies has a 12-month low of $18.72 and a 12-month high of $31.97. The stock has a market capitalization of $9.92 billion, a price-to-earnings ratio of -15.84, a PEG ratio of 0.58 and a beta of 1.02. The company has a current ratio of 1.15, a quick ratio of 0.86 and a debt-to-equity ratio of 9.17.
A number of institutional investors and hedge funds have recently made changes to their positions in BHC. Carolina Wealth Advisors LLC bought a new position in Bausch Health Companies during the fourth quarter valued at approximately $31,000. Bessemer Group Inc. raised its position in Bausch Health Companies by 5,071.8% in the fourth quarter. Bessemer Group Inc. now owns 2,017 shares of the company’s stock worth $60,000 after acquiring an additional 1,978 shares during the period. Aigen Investment Management LP bought a new position in Bausch Health Companies in the fourth quarter worth approximately $95,000. Fieldpoint Private Securities LLC bought a new position in Bausch Health Companies in the fourth quarter worth approximately $104,000. Finally, IFP Advisors Inc raised its position in Bausch Health Companies by 2,293.9% in the fourth quarter. IFP Advisors Inc now owns 3,543 shares of the company’s stock worth $105,000 after acquiring an additional 3,395 shares during the period. Institutional investors and hedge funds own 57.38% of the company’s stock.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: Most Active Stocks
Analyst Recommendations for Bausch Health Companies (NYSE:BHC)
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent BHC News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:24:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:19:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:16:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 03:36:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 10:04:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:04:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:30:26 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/08/2024 02:00:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 10:18:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:19:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:18:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:15:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 09:35:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/05/2023 04:12:39 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/13/2023 09:50:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/06/2023 10:06:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/06/2023 04:09:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:58:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 11:05:39 AM
- Bausch Health Gets FDA Approval for Acne Treatment Cabtreo • Dow Jones News • 10/20/2023 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 08:29:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 08:28:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 08:27:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 08:25:30 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM